On Friday, Galectin Therapeutics Inc (NASDAQ: GALT) opened higher 8.46% from the last session, before settling in for the closing price of $1.30. Price fluctuations for GALT have ranged from $0.73 to $4.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 1.35% at the time writing. With a float of $43.19 million, this company’s outstanding shares have now reached $62.31 million.
Let’s look at the performance matrix of the company that is accounted for 14 employees. In terms of profitability, gross margin is 66.25%, operating margin of -49457.5%, and the pretax margin is -56346.25%.
Galectin Therapeutics Inc (GALT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Galectin Therapeutics Inc is 30.68%, while institutional ownership is 16.19%. The most recent insider transaction that took place on Dec 30 ’24, was worth 7,540. In this transaction Director of this company bought 6,500 shares at a rate of $1.16, taking the stock ownership to the 15,206 shares. Before that another transaction happened on Dec 23 ’24, when Company’s Chief Medical Officer sold 13,654 for $0.88, making the entire transaction worth $12,044. This insider now owns 26,346 shares in total.
Galectin Therapeutics Inc (GALT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.49% during the next five years compared to -14.30% drop over the previous five years of trading.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
Check out the current performance indicators for Galectin Therapeutics Inc (GALT). In the past quarter, the stock posted a quick ratio of 1.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.92 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc (NASDAQ: GALT) saw its 5-day average volume 0.27 million, a negative change from its year-to-date volume of 0.32 million. As of the previous 9 days, the stock’s Stochastic %D was 72.67%. Additionally, its Average True Range was 0.10.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 27.99%, which indicates a significant decrease from 62.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.26% in the past 14 days, which was lower than the 131.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4342, while its 200-day Moving Average is $2.3351. Nevertheless, the first resistance level for the watch stands at $1.5333 in the near term. At $1.6567, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7733. If the price goes on to break the first support level at $1.2933, it is likely to go to the next support level at $1.1767. The third support level lies at $1.0533 if the price breaches the second support level.
Galectin Therapeutics Inc (NASDAQ: GALT) Key Stats
There are currently 62,762K shares outstanding in the company with a market cap of 87.86 million. Presently, the company’s annual sales total 0 K according to its annual income of -41,070 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -11,220 K.
